Dechra Pharmaceuticals PLC announced that, with effect from 1 June 2022, John Shipsey will be appointed as a Non-Executive Director of the Company. John will be a member of the Group's Audit, Remuneration and Nomination Committees with the intention that he will be appointed as Chair of the Audit Committee upon Julian Heslop's retirement as Audit Committee Chairman on 1 September 2022. John has valuable experience leading innovative, high growth companies and brings a wealth of financial and commercial experience to the business.

In addition, his recent tenure as Chief Financial Officer at FTSE100 Smiths Group PLC will be a highly relevant asset to the Board and Dechra.